Our top pick for
argenx SE is a biotechnology business based in the US. argenx shares (ARGX) are listed on the NASDAQ and all prices are listed in US Dollars. argenx employs 336 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$296.02|
|52-week range||$244.98 - $382.15|
|50-day moving average||$314.74|
|200-day moving average||$299.99|
|Wall St. target price||$351.94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.29%|
|1 month (2021-09-21)||-6.43%|
|3 months (2021-07-21)||-7.20%|
|6 months (2021-04-21)||2.31%|
|1 year (2020-10-21)||15.27%|
|2 years (2019-10-21)||157.72%|
|3 years (2018-10-19)||263.66%|
|5 years (2016-10-17)||N/A|
|Revenue TTM||$517.8 million|
|Gross profit TTM||$-270,945,000|
|Return on assets TTM||-4.36%|
|Return on equity TTM||-14.14%|
|Market capitalisation||$15.4 billion|
TTM: trailing 12 months
There are currently 896,000 argenx shares held short by investors – that's known as argenx's "short interest". This figure is 8.6% up from 825,234 last month.
There are a few different ways that this level of interest in shorting argenx shares can be evaluated.
argenx's "short interest ratio" (SIR) is the quantity of argenx shares currently shorted divided by the average quantity of argenx shares traded daily (recently around 198230.08849558). argenx's SIR currently stands at 4.52. In other words for every 100,000 argenx shares traded daily on the market, roughly 4520 shares are currently held short.
However argenx's short interest can also be evaluated against the total number of argenx shares, or, against the total number of tradable argenx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case argenx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 argenx shares in existence, roughly 20 shares are currently held short) or 0.0193% of the tradable shares (for every 100,000 tradable argenx shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against argenx.
Find out more about how you can short argenx stock.
We're not expecting argenx to pay a dividend over the next 12 months.
Over the last 12 months, argenx's shares have ranged in value from as little as $244.98 up to $382.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while argenx's is 0.8087. This would suggest that argenx's shares are less volatile than average (for this exchange).
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S. À. R.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.